Overview

* Sutro Biopharma ( STRO ) Q3 revenue increased to $9.7 mln, primarily from Astellas collaboration

* Company received FDA clearance for STRO-004 IND, plans to dose first patient by year-end

* Operating expenses decreased significantly due to restructuring, extending cash runway to mid-2027

Outlook

* Sutro plans to dose first patient with STRO-004 before year-end

* STRO-006 expected to enter clinical development in 2026

* Sutro targets IND submission for dual-payload ADC program in 2027

Result Drivers

* RESTRUCTURING BENEFITS - Organizational restructuring extends cash runway to mid-2027, supporting ADC focus

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $9.69

Revenue mln

Q3 Net -$56.86

Income mln

Q3 $58.15

Operatin mln

g

Expenses

Q3 -$48.46

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Sutro Biopharma Inc ( STRO ) is $2.00, about 50.8% above its November 5 closing price of $0.98

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)